Accelerated Corneal Cross-Linking With Photoactivated Chromophore for Moderate Therapy-Resistant Infectious Keratitis

Purpose: To evaluate the effect of accelerated corneal cross-linking with photoactivated chromophore (PACK-CXL) as additional treatment for therapy-resistant infectious keratitis. Methods: In this interventional cohort study, 20 patients (11 men and 9 women), aged 65.5 (interquartile range = 21.5–78.5) years, who were hospitalized for moderate-sized therapy-resistant bacterial corneal ulcers (11/20 microbiologically confirmed) were treated with hypoosmolar 0.1% riboflavin solution and Ultraviolet A (UVA) irradiation for 3 minutes at 30 mW/cm2 (5.4 J/cm2) as additional therapy to standard antimicrobial treatment. Results: We did not observe any adverse effects of accelerated PACK-CXL on the corneal stroma or limbus. The median ulcer size was 3.00 (2.63–4.50) mm, the median time to reepithelialization was 6.50 (5.00–18.0) days, and the mean hospitalization period was 8.5 ± 4.5 days. Tectonic keratoplasty became necessary in 1 patient (5%). Conclusions: Our results suggest that accelerated PACK-CXL may provide an antimicrobial effect similar to the 1 low-intensity, slow setting (30 minutes at 3 mW/cm2) and may be used as additional treatment in moderate-sized therapy-resistant infectious keratitis.

[1]  Lamprini Papaioannou,et al.  Corneal Collagen Cross-Linking for Infectious Keratitis: A Systematic Review and Meta-Analysis , 2016, Cornea.

[2]  Farhad Hafezi,et al.  Corneal cross-linking. , 2017, Survey of ophthalmology.

[3]  A. Agarwal,et al.  Increased Biomechanical Efficacy of Corneal Cross-linking in Thin Corneas Due to Higher Oxygen Availability. , 2015, Journal of refractive surgery.

[4]  F. Hafezi,et al.  Long-term Results of an Accelerated Corneal Cross-linking Protocol (18 mW/cm2) for the Treatment of Progressive Keratoconus. , 2015, American journal of ophthalmology.

[5]  J. Schrenzel,et al.  Accelerated photoactivated chromophore for keratitis-corneal collagen cross-linking as a first-line and sole treatment in early fungal keratitis. , 2014, Journal of refractive surgery.

[6]  P. François,et al.  Antibacterial efficacy of accelerated photoactivated chromophore for keratitis-corneal collagen cross-linking (PACK-CXL). , 2014, Journal of refractive surgery.

[7]  F. Hafezi,et al.  PACK-CXL: defining CXL for infectious keratitis. , 2014, Journal of refractive surgery.

[8]  H. Dua,et al.  Collagen cross-linking with photoactivated riboflavin (PACK-CXL) for the treatment of advanced infectious keratitis with corneal melting. , 2014, Ophthalmology.

[9]  F. Hafezi,et al.  Corneal biomechanical properties at different corneal cross-linking (CXL) irradiances. , 2014, Investigative ophthalmology & visual science.

[10]  F. Hafezi,et al.  The Biomechanical Effect of Corneal Collagen Cross-Linking (CXL) With Riboflavin and UV-A is Oxygen Dependent. , 2013, Translational vision science & technology.

[11]  F. Hafezi,et al.  Safety profile of high-fluence corneal collagen cross-linking for progressive keratoconus: preliminary results from a prospective cohort study. , 2013, Journal of refractive surgery.

[12]  S. Beatty,et al.  Risk Factors, Microbiological Findings, and Clinical Outcomes in Cases of Microbial Keratitis Admitted to a Tertiary Referral Center in Ireland , 2009, Cornea.

[13]  W. Camacho,et al.  Antimicrobial efficacy of riboflavin/UVA combination (365 nm) in vitro for bacterial and fungal isolates: a potential new treatment for infectious keratitis. , 2008, Investigative ophthalmology & visual science.

[14]  T. Seiler,et al.  Ultraviolet A/Riboflavin Corneal Cross-linking for Infectious Keratitis Associated With Corneal Melts , 2008, Cornea.

[15]  F. Stapleton,et al.  Risk Factors and Causative Organisms in Microbial Keratitis , 2008, Cornea.

[16]  G. Wollensak,et al.  Crosslinking treatment of progressive keratoconus: new hope , 2006, Current opinion in ophthalmology.

[17]  H. Taylor,et al.  Microbial Keratitis: Predisposing Factors and Morbidity , 2006 .

[18]  F. Mah Fourth-generation fluoroquinolones: new topical agents in the war on ocular bacterial infections , 2004, Current opinion in ophthalmology.

[19]  J. Cadet,et al.  Riboflavin and UV-Light Based Pathogen Reduction: Extent and Consequence of DNA Damage at the Molecular Level , 2004, Photochemistry and photobiology.

[20]  D. Hwang Fluoroquinolone resistance in ophthalmology and the potential role for newer ophthalmic fluoroquinolones. , 2004, Survey of ophthalmology.

[21]  T. Seiler,et al.  Riboflavin/ultraviolet-a-induced collagen crosslinking for the treatment of keratoconus. , 2003, American journal of ophthalmology.

[22]  R. Goodrich The use of riboflavin for the inactivation of pathogens in blood products. , 2000, Vox sanguinis.

[23]  M. Srinivasan,et al.  Corneal ulceration in the developing world—a silent epidemic , 1997, The British journal of ophthalmology.

[24]  R. D. Freeman Oxygen consumption by the component layers of the cornea , 1972, The Journal of physiology.